Sarcomatoid renal cell carcinoma: Biology and treatment advances

被引：48

作者：

El Mouallem, Nemer ^{[1
]}

Smith, Steven C. ^{[2
]}

Paul, Asit K. ^{[1
]}

机构：

[1] Virginia Commonwealth Univ, Div Hematol Oncol & Palliat Care, Massey Canc Ctr, VCU Med Ctr, Richmond, VA 23284 USA

[2] Virginia Commonwealth Univ, Dept Pathol, Massey Canc Ctr, VCU Med Ctr, Richmond, VA USA

来源：

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2018年 / 36卷 / 06期

关键词：

Sarcomatoid renal cell carcinoma; Renal cell carcinoma; Nephrectomy; Chemotherapy; Targeted therapy; Immunotherapy; CYTOREDUCTIVE NEPHRECTOMY; INTERNATIONAL SOCIETY; ANTI-PD-L1; ANTIBODY; PD-L1; EXPRESSION; CANCER; TUMORS; CLASSIFICATION; PATHOLOGY; BIOPSY; SAFETY;

D O I：

10.1016/j.urolonc.2017.12.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sarcomatoid transformation in renal cell carcinoma, so called sacromatoid RCC (sRCC), is associated with an aggressive behavior and a poor prognosis. Current therapeutic approaches are largely ineffective. Recent studies looking into the genomic and molecular characterization of sRCCs have provided insights into the biology and pathogenesis of this entity. These advances in molecular signatures may help development of effective treatment strategies. We herein present a review of recent developments in the pathology, biology, and treatment modalities in sRCC. (C) 2017 Elsevier Inc. All rights reserved.

引用

页码：265 / 271

页数：7

共 50 条

[21] The Role of the Pathologist in Renal Cell Carcinoma Management
Matar, Sayed
El Ahmar, Nourhan
Laimon, Yasmin Nabil
Ghandour, Fatme
Signoretti, Sabina
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (05) : 849 - 862
[22] Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art
Lebacle, Cedric
Pooli, Aydin
Bessede, Thomas
Irani, Jacques
Pantuck, Allan J.
Drakaki, Alexandra
WORLD JOURNAL OF UROLOGY, 2019, 37 (01) : 115 - 123
[23] Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies
Voss, M. H.
Bastos, D. A.
Karlo, C. A.
Ajeti, A.
Hakimi, A. A.
Feldman, D. R.
Hsieh, J. J.
Molina, A. M.
Patil, S.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2014, 25 (03) : 663 - 668
[24] Immune evasion in renal cell carcinoma: biology, clinical translation, future directions
Wang, Xiaoyang
Lopez, Robert
Luchtel, Rebecca A.
Hafizi, Sassan
Gartrell, Benjamin
Shenoy, Niraj
KIDNEY INTERNATIONAL, 2021, 99 (01) : 75 - 85
[25] Sarcomatoid renal cell carcinoma with rhabdoid features
Al-Saidi, Nagla Ahmed
Akhtar, Mohammed
ANNALS OF SAUDI MEDICINE, 2013, 33 (05) : 495 - 499
[26] Advances in non-clear cell renal cell carcinoma management: From heterogeneous biology to treatment options
Wilson, Nathaniel R.
Acikgoz, Yusuf
Hasanov, Elshad
INTERNATIONAL JOURNAL OF CANCER, 2024, 154 (06) : 947 - 961
[27] Sarcomatoid component and the risk of renal cell carcinoma: a systematic review and meta-analysis
Liu, Xingchen
Qi, Ping
Jin, Jianbin
Svatek, Robert
Rodriguez, Ronald
Wang, Zhiping
Yin, Yongsheng
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (06): : 5444 - 5456
[28] Ki-67 index and percentage of sarcomatoid differentiation were two independent prognostic predictors in sarcomatoid renal cell carcinoma
Wang, Zhixian
Zeng, Xiaoyong
Chen, Ruibao
Chen, Zhiqiang
CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 5339 - 5347
[29] Use of PAX8 and GATA3 in diagnosing sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma
Chang, Alex
Brimo, Fadi
Montgomery, Elizabeth A.
Epstein, Jonathan I.
HUMAN PATHOLOGY, 2013, 44 (08) : 1563 - 1568
[30] Comparative analysis of programmed cell death ligand 1 assays in renal cell carcinoma
Lee, Kyu Sang
Choe, Gheeyoung
Yun, Sumi
Lee, Kyoungyul
Moon, Seyoung
Lee, Sangchul
Hong, Sung Kyu
Byun, Seok-Soo
Lee, Sang Eun
HISTOPATHOLOGY, 2020, 77 (01) : 67 - 78

← 1 2 3 4 5 →